Brickell Stock Financials

BBI
 Stock
  

USD 0.10  0.03  23.08%   

Brickell Biotech Average Equity is most likely to decrease significantly in the upcoming years. The last year's value of Average Equity was reported at 24.09 Million. The current Enterprise Value is estimated to increase to about 5.1 M, while Net Income Per Employee is projected to decrease to (1.9 M).
  
Refresh
With this module, you can analyze Brickell financials for your investing period. You should be able to track the changes in Brickell Biotech individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Brickell Most Recent Estimates

Diluted Eps
-0.42
EPS Estimate Current Year
-0.19
EPS Estimate Next Year
-0.19
EPS Estimate Current Quarter
-0.06
Earnings Share
-0.42

Revenues

414,632

Share
Understanding current and past Brickell Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Brickell Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Brickell Biotech's assets may result in an increase in income on the income statement.
The fundamental analysis of Brickell Biotech is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Brickell Biotech includes many different criteria found on its balance sheet. For example, investors should never minimize Brickell Biotech's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Brickell Biotech's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Brickell Biotech.

Brickell Biotech Cash

Chance Of Financial Distress
Less than 3
Brickell Biotech has less than 3 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Brickell Biotech stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Brickell Biotech's official financial statements usually reflect Brickell Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Brickell Biotech. For example, before you start analyzing numbers published by Brickell accountants, it's critical to develop an understanding of what Brickell Biotech's liquidity, profitability, and earnings quality are in the context of the Pharmaceutical Products space in which it operates.
Please note, the presentation of Brickell Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Brickell Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Brickell Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Brickell Biotech. Please utilize our Beneish M Score to check the likelihood of Brickell Biotech's management to manipulate its earnings.

Brickell Biotech Company Summary

Brickell Biotech competes with Abcellera Biologics, Arca Biopharma, Acumen Pharmaceuticals, Absci Corp, and Adicet Bio. Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0000819050
CUSIP10802T105
Older SymbolVICL
RegionNorth America
LocationColorado; U.S.A
Business Address5777 Central Avenue,
New SymbolBBI1
BenchmarkDOW
Websitewww.ir.brickellbio.com
Phone720 505 4755
Related EntityBLIAQ
CurrencyUSD - US Dollar
You should never invest in Brickell Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Brickell Stock, because this is throwing your money away. Analyzing the key information contained in Brickell Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Brickell Biotech Key Financial Ratios

Generally speaking, Brickell Biotech's financial ratios allow both analysts and investors to convert raw data from Brickell Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Brickell Biotech over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Brickell Biotech reports annually and quarterly.

Brickell Biotech Key Balance Sheet Accounts

201720182019202020212022 (projected)
Accounts Payable326 K1.21 M412 K2.25 M2.02 M2.18 M
Total Assets80.49 M8.75 M18.14 M33.63 M29.72 M37.17 M
Current Assets76.32 M8.27 M17.97 M33.53 M29.6 M34.99 M
Assets Non Current4.18 M478 K175 K104 K117 K120.08 K
Cash and Equivalents25.03 M8.07 M7.23 M30.11 M26.88 M24.71 M
Deferred Revenue3.02 M11.7 M9.71 M1.79 M2.06 M3.03 M
Shareholders Equity63.58 M(71.62 M)7.57 M27.14 M24.91 M28.61 M
Investments25.31 M32.6 M37.87 M4.5 M4.05 M4.15 M
Investments Current23.26 M30.55 M35.66 M4.5 M5.17 M5.31 M
Total Liabilities16.92 M22.08 M10.57 M6.5 M4.81 M4.94 M
Current Liabilities16.92 M20.09 M10.5 M6.35 M4.81 M7.32 M

Brickell Biotech Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Brickell Biotech's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses10.93 M6.29 M6.48 M1.44 M1.65 M1.69 M
Consolidated Income(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Gross Profit7.34 M10.89 M7.92 M1.82 M404 K414.63 K
Net Income(12.96 M)(9.24 M)(23.88 M)(20.91 M)(39.47 M)(40.51 M)
Operating Expenses20.73 M19.34 M32.38 M22.8 M40.65 M35.9 M
Operating Income(13.39 M)(8.45 M)(24.47 M)(20.98 M)(40.24 M)(41.3 M)
Revenues13.82 M10.89 M7.92 M1.82 M404 K414.63 K

Brickell Biotech Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Brickell Biotech. It measures of how well Brickell is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Brickell Biotech brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Brickell had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Brickell Biotech has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(80 K)(12 K)(7 K)(23 K)(36 K)(38.84 K)
Depreciation Amortization and Accretion793 K49 K28 K10 K22 K22.58 K
Net Cash Flow or Change in Cash and Cash Equivalents16.65 M2.67 M(835 K)22.88 M(3.23 M)(3.32 M)
Issuance Purchase of Equity Shares30.55 M45 K47 K38 M33 M35.61 M
Net Cash Flow from Financing30.55 M(1.29 M)2.64 M38.44 M32.95 M35.55 M
Net Cash Flow from Investing(5.29 M)(12 K)32.51 M4.48 M(36 K)(36.95 K)
Net Cash Flow Investment Acquisitions and Disposals(7.42 M)(5.21 M)19.5 M4.5 M5.17 M5.58 M
Net Cash Flow from Operations(8.6 M)3.97 M(35.98 M)(20.03 M)(36.15 M)(37.1 M)
Share Based Compensation756 K711 K1.53 M1.99 M2.26 M2.08 M

Brickell Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Brickell Biotech's current stock value. Our valuation model uses many indicators to compare Brickell Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brickell Biotech competition to find correlations between indicators driving Brickell Biotech's intrinsic value. More Info.
Brickell Biotech is rated below average in total asset category among related companies. It is rated below average in price to sales category among related companies . The ratio of Total Asset to Price to Sales for Brickell Biotech is about  2,127,165 . The current Price to Sales Ratio is estimated to increase to 49.10. Comparative valuation analysis is a catch-all model that can be used if you cannot value Brickell Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Brickell Biotech's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brickell Biotech's earnings, one of the primary drivers of an investment's value.

Brickell Biotech Systematic Risk

Brickell Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Brickell Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fifty with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on Brickell Biotech correlated with the market. If Beta is less than 0 Brickell Biotech generally moves in the opposite direction as compared to the market. If Brickell Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Brickell Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Brickell Biotech is generally in the same direction as the market. If Beta > 1 Brickell Biotech moves generally in the same direction as, but more than the movement of the benchmark.
.

About Brickell Biotech Financials

What exactly are Brickell Biotech Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Brickell Biotech's income statement, its balance sheet, and the statement of cash flows. Potential Brickell Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Brickell Biotech is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Brickell grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Brickell Biotech Thematic Clasifications

Brickell Biotech is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical Products Idea
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Brickell Biotech July 3, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Brickell Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Brickell Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Brickell Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Brickell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Brickell Biotech's daily price indicators and compare them against related drivers.
Information Ratio(0.09)
Maximum Drawdown65.2
Value At Risk(16.22)
Potential Upside13.33
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
11.7 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.